Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

Katrien Van Roosbroeck, Luk Cox, Thomas Tousseyn, Idoya Lahortiga, Olga Gielen, Barbara Cauwelier, Pascale De Paepe, Gregor Verhoef, Peter Marynen, Peter Vandenberghe, Chris De Wolf-Peeters, Jan Cools, Iwona Wlodarska

Blood (2011) 117 (15): 4056–4064.

https://doi.org/10.1182/blood-2010-06-291310

Published: 2011

Includes: Supplemental data

Journal Articles

JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma.

Katrien Van Roosbroeck, Luk Cox, PhD, Idoya Lahortiga, PhD, Olga Gielen, Thomas Tousseyn, MD, PhD, Barbara Cauwelier, PhD, Pascale De Paepe, MD, PhD, Peter Vandenberghe, MD, PhD, Peter Marynen, PhD, Chris De Wolf-Peeters, MD, PhD, Jan Cools, PhD, Iwona Wlodarska, PhD

Blood (2009) 114 (22): 140.

https://doi.org/10.1182/blood.V114.22.140.140

Published: 2009

Journal Articles

FIP1L1-PDGFRα D842V, a Novel Panresistant Mutant, Emerges after Treatment of FIP1L1-PDGFRα T674I Eosinophilic Leukemia with Single Agent Sorafenib

Peter Vandenberghe, MD, PhD, Els Lierman, Lucienne Michaux, MD, PhD, Pascal Pierre, MD, Peter Marynen, PhD, Jan Cools, PhD

Blood (2008) 112 (11): 3730.

https://doi.org/10.1182/blood.V112.11.3730.3730

Published: 2008

Journal Articles

Sorafenib Potently Inhibits ETV6-PDGFRβ and FLT3 Mutants, and Shows Activity Against FLT3 Mutants That Are Resistant to Other Small Molecule Inhibitors.

Els Lierman, BSc, Idoya Lahortiga, PhD, Helen Van Miegroet, Nicole Mentens, Peter Marynen, PhD, Jan Cools, PhD

Blood (2006) 108 (11): 1993.

https://doi.org/10.1182/blood.V108.11.1993.1993

Published: 2006

Journal Articles

Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins.

Kim De Keersmaecker, Rafael Bernad, Cedric Folens, Nicole Mentens, Peter Marynen, Maarten Fornerod, Jan Cools

Blood (2006) 108 (11): 1830.

https://doi.org/10.1182/blood.V108.11.1830.1830

Published: 2006

Journal Articles

Array-CGH Analysis of T-ALL Patients and Cell Lines.

Idoya Lahortiga, PhD, Carlos Graux, MD, Nicole Mentens, Katrien Van Roosbroeck, Kim De Keersmaecker, Frederic Lambert, MD, Peter Vandenberghe, MD, Iwona Wlodarska, PhD, Guy Froyen, PhD, Maria D. Odero, PhD, MD, Peter Marynen, PhD, Jan Cools, PhD

Blood (2006) 108 (11): 4469.

https://doi.org/10.1182/blood.V108.11.4469.4469

Published: 2006

Journal Articles

Involvement of the NOTCH1 and NOTCH2 Genes in B-Cell Lymphomagenesis.

Iwona Wlodarska, PhD, Kim De Keersmaecker, Jan Cools, PhD, Chris De Wolf-Peeters, MD,PhD, Andre Bosly, MD,PhD, Monique Delos, MD, Lucienne Michaux, MD,PhD, Peter Vandenberghe, MD,PhD, Anne Hagemeijer, MD,PhD, Peter Marynen, PhD

Blood (2006) 108 (11): 2072.

https://doi.org/10.1182/blood.V108.11.2072.2072

Published: 2006

Journal Articles

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

Els Lierman, Cedric Folens, Elizabeth H. Stover, Nicole Mentens, Helen Van Miegroet, Werner Scheers, Marc Boogaerts, Peter Vandenberghe, Peter Marynen, Jan Cools

Blood (2006) 108 (4): 1374–1376.

https://doi.org/10.1182/blood-2006-02-004457

Published: 2006

Journal Articles

NOTCH1 Is Targeted by Ig Translocations in NHL.

Iwona Wlodarska, PhD, Chris De Wolf-Peeters, MD, PhD, Jan Cools, PhD, Francesca Minnei, MD, Andre Bosly, MD, PhD, Monique Delos, MD, Lucienne Michaux, MD, PhD, Peter Vandenberghe, MD, PhD, Anne Hagemeijer, MD, PhD, Peter Marynen, PhD

Blood (2005) 106 (11): 4339.

https://doi.org/10.1182/blood.V106.11.4339.4339

Published: 2005

Journal Articles

Juxtamembrane Domain Truncation Is Sufficient for Activation of the FIP1L1-PDGFRα and ETV6-PDGFRβ Fusion Kinases.

Elizabeth H. Stover, BA, Jing Chen, PhD, Cedric Folens, Benjamin H. Lee, MD, PhD, Nicole Mentens, Peter Marynen, PhD, D. Gary Gilliland, PhD, MD, Jan Cools, PhD

Blood (2005) 106 (11): 3511.

https://doi.org/10.1182/blood.V106.11.3511.3511

Published: 2005

Journal Articles

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)

Kim De Keersmaecker, Carlos Graux, Maria D. Odero, Nicole Mentens, Riet Somers, Johan Maertens, Iwona Wlodarska, Peter Vandenberghe, Anne Hagemeijer, Peter Marynen, Jan Cools

Blood (2005) 105 (12): 4849–4852.

https://doi.org/10.1182/blood-2004-12-4897

Published: 2005

Journal Articles

FOXP1, a Highly Expressed Gene in a Subset of DLBCL, Is Targeted by a Recurrent t(3;14)(p13;q32).

Iwona Wlodarska, PhD, Peter Vandenberghe, MD PhD, Peet Nooien, MD, Anne Hagemeijer, MD PhD, Peter Marynen, PhD, Chris De Wolf-Peeters, MD PhD

Blood (2004) 104 (11): 2891.

https://doi.org/10.1182/blood.V104.11.2891.2891

Published: 2004

Journal Articles

Chromosomal Rearrangements Affecting ABL1 in T-Cell Acute Lymphoblastic Leukemia.

Jan Cools, PhD, Carlos Graux, MD, Marc Boogaerts, MD, PhD, Peter Vandenberghe, MD, PhD, Iwona Wlodarska, PhD, Peter Marynen, PhD, Anne Hagemeijer, MD, PhD

Blood (2004) 104 (11): 2894.

https://doi.org/10.1182/blood.V104.11.2894.2894

Published: 2004

Journal Articles

Fusion of NUP214 to ABL1 on Amplified Extrachromosomal Elements in T-ALL.

Blood (2004) 104 (11): 141.

https://doi.org/10.1182/blood.V104.11.141.141

Published: 2004

Journal Articles

MHH-TALL1, a T-ALL Cell Line Expressing a Novel BCR-ABL Transcript.

Hilmar Quentmeier, PhD, Jan Cools, PhD, Roderick A.F. MacLeod, PhD, Peter Marynen, PhD, Cord C. Uphoff, PhD, Hans G. Drexler, MD, PhD

Blood (2004) 104 (11): 4390.

https://doi.org/10.1182/blood.V104.11.4390.4390

Published: 2004

Journal Articles

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA –positive chronic eosinophilic leukemia

Jan Cools, Hilmar Quentmeier, Brian J. P. Huntly, Peter Marynen, James D. Griffin, Hans G. Drexler, D. Gary Gilliland

Blood (2004) 103 (7): 2802–2805.

https://doi.org/10.1182/blood-2003-07-2479

Published: 2004

Journal Articles

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma

Pascale De Paepe, Mathijs Baens, Han van Krieken, Bruno Verhasselt, Michel Stul, Annet Simons, Bruce Poppe, Geneviève Laureys, Paul Brons, Peter Vandenberghe, Frank Speleman, Marleen Praet, Chris De Wolf-Peeters, Peter Marynen, Iwona Wlodarska

Blood (2003) 102 (7): 2638–2641.

https://doi.org/10.1182/blood-2003-04-1050

Published: 2003

Journal Articles

MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma

Dolors Sanchez-Izquierdo, Gerard Buchonnet, Reiner Siebert, Randy D. Gascoyne, Joan Climent, Loraine Karran, Miguel Marin, David Blesa, Douglas Horsman, Andreas Rosenwald, Louis M. Staudt, Donna G. Albertson, Ming-Qing Du, Hongtao Ye, Peter Marynen, Javier Garcia-Conde, Daniel Pinkel, Martin J. S. Dyer, Jose Angel Martinez-Climent

Blood (2003) 101 (11): 4539–4546.

https://doi.org/10.1182/blood-2002-10-3236

Published: 2003

Includes: Supplemental data

Journal Articles

Evidence for position effects as a variant ETV6 -mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)

Jan Cools, Nicole Mentens, Maria D. Odero, Pieter Peeters, Iwona Wlodarska, Michel Delforge, Anne Hagemeijer, Peter Marynen

Blood (2002) 99 (5): 1776–1784.

https://doi.org/10.1182/blood.V99.5.1776

Published: 2002

Journal Articles

Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes

Judith Dierlamm, Mathijs Baens, Margarita Stefanova-Ouzounova, Kristina Hinz, Iwona Wlodarska, Brigitte Maes, Anja Steyls, Ann Driessen, Gregor Verhoef, Philippe Gaulard, Anne Hagemeijer, Dieter Kurt Hossfeld, Christiane De Wolf-Peeters, Peter Marynen

Blood (2000) 96 (6): 2215–2218.

https://doi.org/10.1182/blood.V96.6.2215

Published: 2000

NARROW

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma.

FIP1L1-PDGFRα D842V, a Novel Panresistant Mutant, Emerges after Treatment of FIP1L1-PDGFRα T674I Eosinophilic Leukemia with Single Agent Sorafenib

Sorafenib Potently Inhibits ETV6-PDGFRβ and FLT3 Mutants, and Shows Activity Against FLT3 Mutants That Are Resistant to Other Small Molecule Inhibitors.

Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins.

Array-CGH Analysis of T-ALL Patients and Cell Lines.

Involvement of the NOTCH1 and NOTCH2 Genes in B-Cell Lymphomagenesis.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

NOTCH1 Is Targeted by Ig Translocations in NHL.

Juxtamembrane Domain Truncation Is Sufficient for Activation of the FIP1L1-PDGFRα and ETV6-PDGFRβ Fusion Kinases.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)

FOXP1, a Highly Expressed Gene in a Subset of DLBCL, Is Targeted by a Recurrent t(3;14)(p13;q32).

Chromosomal Rearrangements Affecting ABL1 in T-Cell Acute Lymphoblastic Leukemia.

Fusion of NUP214 to ABL1 on Amplified Extrachromosomal Elements in T-ALL.

MHH-TALL1, a T-ALL Cell Line Expressing a Novel BCR-ABL Transcript.

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA –positive chronic eosinophilic leukemia

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma

MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma

Evidence for position effects as a variant ETV6 -mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)

Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only